CSPC Pharmaceutical Group (HKSE:01093) EV-to-EBIT : 7.96 (As of Apr. 29, 2024)

View and export this data going back to 1994. Start your Free Trial

What is CSPC Pharmaceutical Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CSPC Pharmaceutical Group's Enterprise Value is HK$64,892 Mil. CSPC Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$8,151 Mil. Therefore, CSPC Pharmaceutical Group's EV-to-EBIT for today is 7.96.

The historical rank and industry rank for CSPC Pharmaceutical Group's EV-to-EBIT or its related term are showing as below:

HKSE:01093' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.64 Med: 10.34 Max: 48.34
Current: 7.96

During the past 13 years, the highest EV-to-EBIT of CSPC Pharmaceutical Group was 48.34. The lowest was 6.64. And the median was 10.34.

HKSE:01093's EV-to-EBIT is ranked better than
81.44% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs HKSE:01093: 7.96

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. CSPC Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2023 was HK$74,855 Mil. CSPC Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$8,151 Mil. CSPC Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 10.89%.

CSPC Pharmaceutical Group EV-to-EBIT Historical Data

The historical data trend for CSPC Pharmaceutical Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group EV-to-EBIT Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

21.35

11.33

10.63

9.96

9.23

CSPC Pharmaceutical Group Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															9.96	10.61	8.30	8.11	9.23

Competitive Comparison of CSPC Pharmaceutical Group's EV-to-EBIT

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSPC Pharmaceutical Group's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's EV-to-EBIT falls into.

CSPC Pharmaceutical Group EV-to-EBIT Calculation

CSPC Pharmaceutical Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	64891.695	/	8150.632
	=	7.96

CSPC Pharmaceutical Group's current Enterprise Value is HK$64,892 Mil.
CSPC Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$8,151 Mil.

CSPC Pharmaceutical Group (HKSE:01093) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CSPC Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	8150.632	/	74855.364
	=	10.89 %

CSPC Pharmaceutical Group's Enterprise Value for the quarter that ended in Dec. 2023 was HK$74,855 Mil.
CSPC Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$8,151 Mil.

CSPC Pharmaceutical Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CSPC Pharmaceutical Group (HKSE:01093) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (HKSE:01093) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CSPCY:USA CHJTF:USA CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (HKSE:01093) Headlines

No Headlines